Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 10/20 | 0.67 |
| ▸ | JAK2 | O60674 | 7/20 | 0.67 |
| ▸ | JAK1 | P23458 | 4/20 | 0.67 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368101 | 0.92 | SMN1; SMN2 (0.65) | TYK2JAK2JAK1ANO1P2RX4 | |
| SCHEMBL30368230 | 0.86 | JAK2 (0.62) | TYK2JAK2JAK1ANO1P2RX4 | |
| SCHEMBL30368235 | 0.86 | JAK2 (0.55) | TYK2JAK2JAK1ANO1 | |
| SCHEMBL30402902 | 0.81 | ANO1 (0.58) | TYK2JAK2JAK1ANO1RECQL | |
| SCHEMBL3514474 | 0.81 | TYK2 (1.00) | TYK2JAK2JAK1 | |
| SCHEMBL30368210 | 0.80 | ANO1 (0.65) | TYK2JAK2JAK1ANO1P2RX4 | |
| SCHEMBL30368260 | 0.79 | ANO1 (0.53) | TYK2JAK2JAK1ANO1RECQL | |
| SCHEMBL30368345 | 0.78 | JAK2 (0.52) | TYK2JAK2JAK1ANO1 | |
| SCHEMBL30368264 | 0.78 | JAK2 (0.55) | TYK2JAK2JAK1ANO1 | |
| SCHEMBL13165570 | 0.78 | TYK2 (0.66) | TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |